News

 

Sigma-Tau Pharmaceuticals, Inc. Newsroom

The Sigma-Tau Newsroom is the single location to learn latest developments about the company, its research, as well as important discoveries in the understanding and treatment of rare diseases.

August 4, 2016 Sigma-Tau Pharmaceuticals, Inc. Appoints Michael Minarich as Chief Executive Officer
April 1, 2015 Sigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for STP-206 For Prevention of Necrotizing Enterocolitis
March 30, 2015 Sigma-Tau Pharmaceuticals, Inc. Receives Orphan Drug Designation for EZN-2279 for Treatment of Adenosine deaminase–deficient Severe Combined Immunodeficiency Disease
August 11, 2014 Sigma-Tau Pharmaceuticals, Inc. Signs Exclusive Agreement with Crosscare Limited for U.S. Marketing and Distribution License of Colief® Infant Drops for the Treatment of Colic-Associated Crying
July 31, 2014 Walgreens Named Exclusive Specialty Pharmacy Provider for Sigma-Tau Pharmaceuticals, Inc.’s, Prescription Drugs: Adagen®, Cystaran® and Matulane®
February 04, 2014 Sigma-Tau Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants.
September 16, 2013 Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
May 15, 2013 Sigma-Tau receives innovation award from the National Organization for Rare Disorders for its advancements in Rare Diseases
May 01, 2013 Sigma-Tau Pharmaceuticals launches Cystaran for the treatment of corneal cystine crystal accumulation in patients with cystinosis
April 29, 2013 Dave Lemus promoted to Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
February 28, 2013 Sigma-Tau Pharmaceuticals Stands United with Patient Organizations on Rare Disease Day.
October 29, 2012 Sigma-Tau Pharmaceuticals, Inc. Announces Appointment of New Vice President of Commercial Operations.
October 16, 2012 Sigma-Tau Pharmaceuticals, Inc. Announces the U.S. Launch of VSL#3® JUNIOR.
October 09, 2012 Sigma-Tau Pharmaceuticals, Inc. Offers New Co-Pay Assistance Program for ADAGEN® Patients.
October 04, 2012 Sigma-Tau Pharmaceuticals, Inc. receives FDA approval of Cystaran™ (cysteamine ophthalmic solution) 0.44% for treatment of corneal cystine crystals in cystinosis patients.
March 09, 2012 Dave Lemus appointed Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc.
February 29, 2012 Sigma-Tau Pharmaceuticals Observes Rare Disease Day
October 27, 2011
Malaria Sigma Tau Group receives European Medicines Agency (EMA) approval of Eurartesim®, a new treatment for uncomplicated P. falciparum malaria.


NEWS ARCHIVES